Clinical trials: SARS-CoV-2 Infections
Covid19
Evaluating the Impact of EnteraGam In People With COVID-19
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019.
- Trial name
- PICNIC (NCT04682041)
- Testing
- Bovine Plasma-Derived Immunoglobulin Concentrate, Standard of care
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Entera Health, Inc
Covid19, COVID-19 Lower Respiratory Infection
In-patient COVID-19 Study of Intranasal Foralumab
This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.
- Conditions
- Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
- Trial name
- NCT04983446
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Coronavirus Infection, COVID-19
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
The search for novel therapies to address the ongoing coronavirus (COVID-19) pandemic is ongoing. No proven therapies have been identified to prevent progression of the virus.
- Conditions
- Coronavirus Infection, COVID-19, Pneumonia, Viral
- Trial name
- NCT04358588
- Testing
- iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System
- Sponsor
- Bellerophon
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
SARS-CoV2 Infection, COVID-19
IMM-BCP-01 in Mild to Moderate COVID-19
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
- Trial name
- NCT05429021
- Testing
- IMM-BCP-01
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Immunome, Inc.
COVID-19
Phase I Double-blind, Placebo-controlled Study of AZD7442
AZD7442 mAbs are being evaluated for administration to prevent or treat COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD7442.
- Trial name
- NCT04896541
- Testing
- AZD7442 300 mg IM(male), AZD7442 600 mg IM (male), AZD7442 300 mg IV (male and female)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
Oestrogen Treatment for COVID-19 Symptoms
The aim of this trial is to determine whether oestrogen treatment mitigates disease progression and severity in confirmed COVID19.
- Trial name
- NCT04853069
- Testing
- Transdermal estradiol gel
- Where
- Qatar
- Volunteers
- 2,000 people
- Sponsor
- Hamad Medical Corporation
SARS-CoV-2 Infection, Fibrosis Lung
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
The innovative drug Treamid is planned for use in the rehabilitation of patients after COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to assess the efficacy and…
- Trial name
- NCT04527354
- Testing
- Treamid
- Where
- 8 sites in Russia
- Volunteers
- 60 people
- Sponsor
- PHARMENTERPRISES LLC
COVID-19 Infection
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection.
- Trial name
- NCT04639466
- Testing
- Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Where
- 3 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- GeoVax, Inc.
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19
Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine
RT-CoV-2 is a Phase I, open-label, dose escalation multicenter clinical trial to assess safety and immunogenicity of the candidate Coronavirus disease (COVID-19) vaccine GRAd-COV2 in Italian healthy volunteers aged 18-55 years…
- Trial name
- NCT04528641
- Testing
- GRAd-COV2
- Where
- 2 sites in Italy
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm…
- Trial name
- NCT05308602
- Testing
- SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Coronavirus, Corona Virus Infection
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and prophylaxis/treatment in health care workers because…
- Trial name
- NCT04353037
- Testing
- Group 1 HCQ
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- UnitedHealth Group
COVID-19, SARS-CoV-2 Acute Respiratory Disease
A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.
- Trial name
- NCT05246137
- Testing
- COVID-19 Vaccine 40 ug/dose
- Where
- 18 sites in Italy, Spain
- Volunteers
- 2,646 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.
This Phase I study is a double-blind, randomized, placebo-controlled study designed to assess the safety, tolerability and PK profile of single intramuscular doses of DWRX2003 in healthy volunteers.
- Trial name
- NCT04749173
- Testing
- DWRX2003, 96mg, DWRX2003, 432mg, DWRX2003, 144mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
COVID-19
Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease
This clincial trial is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial in hospitalized patients with moderate to severe COVID-19 corresponding to score 5 or 6 on the WHO 10-point clinical…
- Trial name
- ASUCOV (NCT05639192)
- Testing
- Asunercept
- Where
- 39 sites in Austria, France and 7 more
- Volunteers
- 34 people
- Sponsor
- Apogenix GmbH
Pharmacokinetics, Safety Issues
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
Pharmacokinetics, safety and efficacy study of GP30341, 200 mg capsules (GEROPHARM LLC, Russia) in healthy volunteers and patients with novel coronavirus infection 2019 (COVID-19) with a high risk of adverse outcome
- Conditions
- Pharmacokinetics, Safety Issues, Efficacy
- Trial name
- NCT05648799
- Testing
- GP30341 capsules 200 mg, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Geropharm
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation